beta Amyloid 1-16 Antikörper
-
- Target
- beta Amyloid 1-16
- Reaktivität
- Human, Maus
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Unkonjugiert
-
Applikation
- Western Blotting (WB), Immunofluorescence (IF), Immunoprecipitation (IP), Immunohistochemistry (IHC), ELISA
- Spezifität
- Reacts with humanand mouse Aβ1-16 as well as other Aβ peptides: Aβ37, Aβ38, Aβ39, Aβ40 and Aβ42
- Aufreinigung
- Purified
- Immunogen
- Synthetic peptide corresponding to Abeta1-16.
- Klon
- Ab3
- Isotyp
- IgG1
-
-
- Applikationshinweise
-
Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only:
1 - 10 μg/mL for any applications - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS, pH 7.4.
- Handhabung
- Dilute in PBS or medium which is identical to that used in the assay system.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Stable for at least one year at -20°C
- Haltbarkeit
- 12 months
-
- Target
- beta Amyloid 1-16
- Andere Bezeichnung
- Amyloid beta 1-16
- Hintergrund
-
Accumulation and aggregation of amyloid β (Aβ) in the brain is indicated as the trigger of a pathological cascade that causes Alzheimer disease (AD). There is now compelling evidence that metal binding to Aβ is involved in AD pathogenesis. The amino acid region 1-16 is widely considered as the metal binding domain of Aβ. Unlike copper(II) that prefers the N-terminal amino group as the main binding site, zinc(II) is preferentially placed in the 8-16 amino acidic region of Aβ (1-16).
Amyloid beta A4 protein ABPP APPI, APP Alzheimer disease amyloid protein Cerebral vascular amyloid peptide, CVAP PreA4 Protease nexin-II, PN-II Gene name: APP, A4, AD1 - Gen-ID
- 351
- UniProt
- P05067
-